FDA Panel To Review Prestwick's Xenazine For Huntington's Chorea
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Peripheral and Central Nervous Systems Advisory Committee assesses the risk-benefit profile of tetrabenazine for the indication Dec. 7.
You may also be interested in...
Prestwick’s Xenazine For Huntington’s Chorea Gets Positive Vote From FDA Panel
FDA’s Peripheral and CNS Drug advisory panel votes unanimously that adverse events associated with the Huntington’s disease treatment do not trump the drug’s proven efficacy.
Prestwick’s Xenazine For Huntington’s Chorea Gets Positive Vote From FDA Panel
FDA’s Peripheral and CNS Drug advisory panel votes unanimously that adverse events associated with the Huntington’s disease treatment do not trump the drug’s proven efficacy.
Prestwick's Xenazine Faces Advisory Committee Review
Huntington's disease treatment tetrabenazine received an FDA "approvable" letter March 24.